Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Ogi

P2.01-005 a Randomized Phase II Trial of Erlotinib vs S-1 in Patients With NSCLC as Third- Or Fourth-Line Therapy (HOT1002)

Journal of Thoracic Oncology

English

Related publications

A Phase II Trial of Docetaxel and Erlotinib as First-Line Therapy for Elderly Patients With Androgen-Independent Prostate Cancer

English

Cetuximab and Irinotecan as Third-Line Therapy in Advanced Colorectal Cancer Patients: A Single Centre Phase II Trial

British Journal of Cancer

Cancer Research

Oncology

2006

English

Randomized Phase II Trial of First-Line Treatment With Tailored Irinotecan and S-1 Therapy Versus S-1 Monotherapy for Advanced or Recurrent Gastric Carcinoma (JFMC31-0301)

English

OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial

Journal of Thoracic Oncology

English

Phase II Trials of Erlotinib or Gefitinib in Patients With Recurrent Meningioma

Journal of Neuro-Oncology

English

Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial

English

Phase I/Ii Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)

English

A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer

Clinical Cancer Research

Cancer Research

Oncology

2008

English

Randomized Phase II Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild‐Type Non‐Small Cell Lung Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Ogi

P2.01-005 a Randomized Phase II Trial of Erlotinib vs S-1 in Patients With NSCLC as Third- Or Fourth-Line Therapy (HOT1002)

Related publications

A Phase II Trial of Docetaxel and Erlotinib as First-Line Therapy for Elderly Patients With Androgen-Independent Prostate Cancer

Cetuximab and Irinotecan as Third-Line Therapy in Advanced Colorectal Cancer Patients: A Single Centre Phase II Trial

Randomized Phase II Trial of First-Line Treatment With Tailored Irinotecan and S-1 Therapy Versus S-1 Monotherapy for Advanced or Recurrent Gastric Carcinoma (JFMC31-0301)

OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial

Phase II Trials of Erlotinib or Gefitinib in Patients With Recurrent Meningioma

Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial

Phase I/Ii Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)

A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer

Randomized Phase II Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild‐Type Non‐Small Cell Lung Cancer